Vol. 19 No. 1 (2015)
CORONARY ARTERY DISEASES

3-year outcomes of endocardial implantation of autologous bone marrow mononuclear cells in cad patients with normal ejection fraction value

PDF (Русский)
  • A. Chernyavskiy,
  • Ye. Kliver,
  • Ye. Pokushalov,
  • A. Romanov,
  • I. Terekhov
A. Chernyavskiy
Academician Ye. Meshalkin Novosibirsk Research Institute of Circulation Pathology
Bio
Ye. Kliver
Academician Ye. Meshalkin Novosibirsk Research Institute of Circulation Pathology
Bio
Ye. Pokushalov
Academician Ye. Meshalkin Novosibirsk Research Institute of Circulation Pathology
Bio
A. Romanov
Academician Ye. Meshalkin Novosibirsk Research Institute of Circulation Pathology
Bio
I. Terekhov
Academician Ye. Meshalkin Novosibirsk Research Institute of Circulation Pathology
Bio
DOI: https://doi.org/10.21688/1681-3472-2015-1-59-65

Published 2015-10-10

Keywords

  • AUTOLOGOUS BONE MARROW MONONUCLEAR CELLS,
  • HEART FAILURE,
  • CORONARY HEART DISEASE

How to Cite

Chernyavskiy, A., Kliver, Y., Pokushalov, Y., Romanov, A., & Terekhov, I. (2015). 3-year outcomes of endocardial implantation of autologous bone marrow mononuclear cells in cad patients with normal ejection fraction value. Patologiya Krovoobrashcheniya I Kardiokhirurgiya, 19(1), 59–65. https://doi.org/10.21688/1681-3472-2015-1-59-65

Copyright (c) 2015 Chernyavskiy A.M., Kliver Ye.N., Pokushalov Ye.A., Romanov A.B., Terekhov I.N.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Objectives. 3-year research data on transendocardial implantation of autologous bone marrow mononuclear cells (ABMMC) in CAD patients with a preserved systolic function of the left ventricle (LV) were analyzed.
Methods. The study included 30 patients with post-infarction cardiosclerosis, with their LV EF varying from 50 % to 70 %. To administer an average 41±16 x 10 6 dose of ABMMC into the myocardial infarction borderline, the NOGA system was used.
Results. Lethality at 36 months was 6.6 % (2 patients) and both cases were not related to the main pathology. Within 36 months of ABMMC implantation, the functional class of angina improved from с 2.8±0.1 to 2.1±0.1 (р<0.05) and NYHA functional class decreased from 2.8±0.1 to 2.3±0.1 (p<0.05). After 36 postoperative months, in most patients the cumulative myocardial perfusion observed at 12 months remained the same in the ABMMC segments. Transendocardial implantation is a safe intervention that improves patients hemodynamic parameters and quality of life.

PDF (Русский)

References

  1. Бокерия Л.А. Минимально инвазивная хирургия сердца. М., 1998.
  2. Беленков Ю.Н. Дисфункция левого желудочка у больных с ишемической болезнью сердца: современные методы диагностики, медикаментозной и немедикаментозной коррекции // Рус. мед. журн. 2000. Т. 3. № 17. С. 685-693.
  3. Беленков Ю.Н. Ремоделирование левого желудочка: комплексный подход // Сердечная недостаточность. 2002. Т. 3. № 4. С. 161-169.
  4. Tse H.F., Kwong Y.L., Chan J.K. et al. Angiogenesis in ischemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation // Lancet. 2003. Vol. 361. Р. 47-49.
  5. Смолянинов А.Б., Горелов А.И. Кардиология будущего и клеточная терапия. СПб., 2006.
  6. Кливер Е.Н., Чернявский А.М., Покушалов и др. Отдаленные результаты трансэндокардиальной клеточной кардиомиопластики у пациентов с выраженной ишемической дисфункцией миокарда // Вестник НГУ. Биология, клиническая медицина. Т. 10. № 3. 2012. С. 105-112.
  7. Liu Y., Guo J., Zhang P. Bone marrow mononuclear cell transplantation into heart elevates the expression of angiogenic factors // Microvasc. Res. 2004. Vol. 68. P. 156-160.
  8. Бураковский В.И. Первые шаги. Записки кардиохирурга. М., 1988.
  9. Fuchs S., Satler L.F., Kornowski R. Catheter-based autologous bone marrow myocardial injection in no-option patients with advanced coronary artery disease // J. Am. Coll. Cardiol. 2003. Vol. 41. Р. 1721-1724.
  10. Perin E.C., Dohmann H.F., Borojevic R. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure // Circulation. 2003. Vol. 107. Р. 2294-2302.
  11. Perin E.C., Dohmann, H.F., Borojevic R. Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy // Circulation. 2004. Vol. 110 (suppl. II). Р. 213-218.
  12. Beeres S., Bax J., Dibbets P. et al. Effect of Intramyocardial Injection of Autologous Bone Marrow-Derived Mononuclear Cells on Perfusion, Function, and Viability in Patients with Drug-Refractory Chronic Ischemia // J. Nucl. Med. 2006. Vol. 47. Р. 574-580.
  13. Weintraub W.S., Jones E.L., Craver J.M. Frequency of repeat coronary bypass or coronary angiogplasty after coronary artery bypass surgery using saphenous venous grafts // Am. J. Cardiol. 1994. Vol. 73. P. 103-108.
  14. Silva G., Perin E., Dohmann H. et al. Catheter-based transendocardial delivery of autologous bone-marrow-derived mononuclear cells in patients listed for heart transplantation // Texas Heart. Inst. 2004. Vol. 31. P. 214-219.
  15. Стрельников А.Г., Романов А.Б., Артеменко С.Н., Лосик Д.В., Гражданкин И.О., Камиев Р.Т., Туров А.Н., Покушалов Е.А. Коррекция последствий инфаркта миокарда при помощи интрамиокардиальных инъекций аутологичных стволовых клеток-предшественниц костного мозга // Патология кровообращения и кардиохирургия. 2013. № 4. С. 37-41.